Here is our next video about Merck stock analysis for the rest of 2021. Merck stock jumped more than 12% on Friday, October 1st, after the company announced that its Molnupiravir pill reduces the risk of hospitalization and death by 50% for patients with mild to moderate Covid-19.

Merck stock today is trading slightly lower pre-market at $82.79 after closing at $83.10 yesterday. Based on these encouraging results, the company rushed to gain regulatory approvals. If approved, the pill would be a game-changer for the entire healthcare sector as per the Merck stock price analysis.

Another interesting Merck stock news is that the shares of vaccine makers like Moderna plummeted 11% in Friday’s trade, respectively, which shows the pill would be a more desirable option for people compared to vaccines in fighting Covid-19 - a potential positive development for Merck stock 2021.

The Covid-19 pill opportunity is huge for Merck stock price and Merck shares could move much higher than the initial 12%.

Watch‌ ‌the‌ ‌full‌ ‌video‌ ‌for‌ ‌our‌ ‌take‌ ‌on‌ Merck shares 2021 and‌ ‌‌a‌ ‌deeper‌ ‌insight‌ ‌into‌ ‌what‌ ‌to‌ ‌expect‌ ‌in‌ ‌the‌ ‌weeks‌ ‌ahead‌ ‌from‌ ‌our‌ Merck stock forecast.‌ ‌Drop‌ ‌us‌ ‌a‌ ‌line‌ ‌in‌ ‌the‌ ‌comments‌ ‌with‌ ‌your‌ ‌thoughts‌ ‌on‌ Merck stock predictions.
‌
To‌ ‌be‌ ‌notified‌ ‌about‌ ‌the‌ ‌latest‌ Merck stock price forecast and ‌news,‌ ‌subscribe‌ ‌to‌ Capital.com Stocks,‌ ‌and‌ ‌click‌ ‌that‌ ‌notification‌ ‌bell.‌

#MerckStock
#MerckStockPrice
#MRK

00:00 Intro
01:52 Merck Antiviral Covid-19 Pill
03:49 Support and resistance
04:23 Technical analysis
08:14 Recap

***
Explore trading and start investing with Capital.com.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.77% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

свернуть